AEVI-007 is a fully human anti-IL-18 monoclonal antibody and is being evaluated since March 2021 in a phase 1b multicentre, open-label study to evaluate safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics in patients with AOSD. The gene discussed is IL18; the disease is adult-onset Still disease.